Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018

April 9, 2018, SOUTH SAN FRANCISCO, Calif.,

Read More

Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer

March 5, 2018, South San Francisco, CA March 5, 2018

Read More

Second Genome Strengthens R&D Program in Immuno-Oncology with Four Academic Collaborations

February 28, 2018, Feb. 28, 2018

Read More